Cargando…
RgIA4 Prevention of Acute Oxaliplatin-Induced Cold Allodynia Requires α9-Containing Nicotinic Acetylcholine Receptors and CD3(+) T-Cells
Chemotherapy-induced neuropathic pain is a debilitating and dose-limiting side effect. Oxaliplatin is a third-generation platinum and antineoplastic compound that is commonly used to treat colorectal cancer and commonly yields neuropathic side effects. Available drugs such as duloxetine provide only...
Autores principales: | Huynh, Peter N., Christensen, Sean B., McIntosh, J. Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688540/ https://www.ncbi.nlm.nih.gov/pubmed/36428990 http://dx.doi.org/10.3390/cells11223561 |
Ejemplares similares
-
RgIA4 Potently Blocks Mouse α9α10 nAChRs and Provides Long Lasting Protection against Oxaliplatin-Induced Cold Allodynia
por: Christensen, Sean B., et al.
Publicado: (2017) -
RgIA4 Accelerates Recovery from Paclitaxel-Induced Neuropathic Pain in Rats
por: Huynh, Peter N., et al.
Publicado: (2019) -
Conopeptides [V11L;V16D]ArIB and RgIA4: Powerful Tools for the Identification of Novel Nicotinic Acetylcholine Receptors in Monocytes
por: Grau, Veronika, et al.
Publicado: (2019) -
Substitution of D-Arginine at Position 11 of α-RgIA Potently Inhibits α7 Nicotinic Acetylcholine Receptor
por: Wu, Yong, et al.
Publicado: (2023) -
Crystal Structure of the Monomeric Extracellular Domain of α9 Nicotinic Receptor Subunit in Complex With α-Conotoxin RgIA: Molecular Dynamics Insights Into RgIA Binding to α9α10 Nicotinic Receptors
por: Zouridakis, Marios, et al.
Publicado: (2019)